APP and Alzheimer disease: The use of β- or γ-secretase inhibitors blocked Aβ production and prevented associated tau pathology in neural cells from human induced pluripotent stem cells (hiPSCs) of AD patients, suggesting aberrant APP processing contributes to Aβ and tau formation [101,102].